Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL by Lina Hamadeh, Amir Enshaei, Claire Schwab,

Slides:

Advertisements

Similar presentations

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL by Arian.

Advertisements

Volume 10, Issue 2, Pages (February 2009)

Volume 10, Issue 2, Pages (February 2009)

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry by Hemant Kulkarni, Vincent C. Marconi,

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

by Sandra Luna-Fineman, Kevin M. Shannon, Susan K

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study by Jasmijn D. E. de Rooij, Riccardo.

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents by Marcin W. Wlodarski, Shinsuke.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Volume 15, Issue 8, Pages (July 2014)

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Arjun Pennathur, MD, Liqiang Xi, MD, Virginia R. Litle, MD, William E

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL by Christian H. Geisler, Mars.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

Leonardo P. de Carvalho et al. BTS 2018;3:

Volume 17, Issue 1, Pages (January 2010)

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants

Salvatore T. Scali, MD, Diego Ayo, MD, Kristina A

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

Mintu P. Turakhia et al. JACEP 2016;2:

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Prabhat Kumar et al. JACEP 2016;j.jacep

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group by Tao Wu, Yong Yang, Su-Yu.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen by Haris Ali, Ibrahim Aldoss, Dongyun.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

by Michael R. DeBaun, and Ellen Wright Clayton

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study by Sarah Wagner, Jayakumar Vadakekolathu, Sarah.

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation by Yoshihiro Inamoto, Tomohiro Matsuda, Ken Tabuchi,

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Impact of age on clinical risk scores in follicular lymphoma

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia by Ondrej Hrusak, Valerie de Haas, Jitka Stancikova,

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

The ROC curves analyzing the sensitivity and specificity of rCBVmax values in astrocytomas for 1-year survival (A) and recurrence (B) show the optimal.

A and B, The ROC curves analyzing the sensitivity and specificity of the WHO grading system (I-IV) for the 1-year survival (A) and recurrence (B) show.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

Daniele Muser et al. JACEP 2017;j.jacep

Patient stratification using survival risk prediction and BCLC staging

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

How I treat T-cell acute lymphoblastic leukemia in adults

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Cold agglutinin disease

Outcomes in patients with PTCL

Presentation transcript:

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL by Lina Hamadeh, Amir Enshaei, Claire Schwab, Cristina N. Alonso, Andishe Attarbaschi, Gisela Barbany, Monique L. den Boer, Judith M. Boer, Marcin Braun, Luciano Dalla Pozza, Sarah Elitzur, Mariana Emerenciano, Larisa Fechina, Maria Sara Felice, Eva Fronkova, Irén Haltrich, Mats M. Heyman, Keizo Horibe, Toshihiko Imamura, Marta Jeison, Gábor Kovács, Roland P. Kuiper, Wojciech Mlynarski, Karin Nebral, Ingegerd Ivanov Öfverholm, Agata Pastorczak, Rob Pieters, Henriett Piko, Maria S. Pombo-de-Oliveira, Patricia Rubio, Sabine Strehl, Jan Stary, Rosemary Sutton, Jan Trka, Grigory Tsaur, Nicola Venn, Ajay Vora, Mio Yano, Christine J. Harrison, and Anthony V. Moorman BloodAdv Volume 3(2):148-157 January 22, 2019 © 2019 by The American Society of Hematology

Lina Hamadeh et al. Blood Adv 2019;3:148-157 © 2019 by The American Society of Hematology

Definition of the cytogenetic, copy number alteration and integrated classifications used in this study. Definition of the cytogenetic, copy number alteration and integrated classifications used in this study. Definition of the classifiers used in the current study: cytogenetic (A), UKALL-CNA (B), and original genetic risk (C). CYTO, cytogenetic; GEN, genetics; GR, good risk; IR, intermediate risk; PR, poor risk. Lina Hamadeh et al. Blood Adv 2019;3:148-157 © 2019 by The American Society of Hematology

Outcome of 3239 patients in the iBFM cohort stratified by the UKALL-CNA classifier. Outcome of 3239 patients in the iBFM cohort stratified by the UKALL-CNA classifier. (A-B) Kaplan-Meier survival curves (A) and forest plots depicting the hazard ratio and 95% CI from univariate Cox regression models comparing the EFS for CNA-GR or CNA-PR against CNA-IR (B). Patients in the Israeli National Study were excluded from the forest plot, as no event occurred in the CNA-GR or CNA-IR groups. DCOG, Dutch Childhood Oncology Group. Lina Hamadeh et al. Blood Adv 2019;3:148-157 © 2019 by The American Society of Hematology

Outcome of 3239 patients in the iBFM cohort stratified by the original genetic risk group. Outcome of 3239 patients in the iBFM cohort stratified by the original genetic risk group. (A-B) Kaplan-Meier survival curves (A) and forest plot (B) depicting the hazard ratio and 95% confidence interval from univariate Cox regression models comparing the EFS for GEN-PR vs GEN-GR. Patients in the Israeli National Study were excluded from the forest plot, as no event occurred in the GEN-GR group. Lina Hamadeh et al. Blood Adv 2019;3:148-157 © 2019 by The American Society of Hematology

Integration of cytogenetic and CNA subgroups using the 3239 patients in the iBFM cohort reveals a new genetic risk classification. Integration of cytogenetic and CNA subgroups using the 3239 patients in the iBFM cohort reveals a new genetic risk classification. (A) EFS of the 9 subgroups derived from cross-tabulating the 3 cytogenetic and 3 CNA risk groups. (B) Visualized inspection of these curves reveals 4 overall genetic risk groups. (C) EFS of the revised genetic risk groups, which are significantly different from one another. Lina Hamadeh et al. Blood Adv 2019;3:148-157 © 2019 by The American Society of Hematology

Outcome of 1405 patients in the iBFM cohort with IR cytogenetics classified according to their CNA profile. Outcome of 1405 patients in the iBFM cohort with IR cytogenetics classified according to their CNA profile. (A-B) Kaplan-Meier survival curves (A) and forest plot (B) depicting the hazard ratio and 95% confidence interval from univariate Cox regression models comparing the EFS for group B (CYTO-IR/CNA-IR and CYTO-IR/CNA-PR) vs group A (CYTO-IR/CNA-GR). Patients in the Israeli National and Sweden studies were excluded from the forest plot, as no event occurred in group B. Lina Hamadeh et al. Blood Adv 2019;3:148-157 © 2019 by The American Society of Hematology